The Hazards of Hazardous Drug Labeling: Time to Revisit Hydroxyurea? | oneSCDvoice
  • Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials
scientific articles

The Hazards of Hazardous Drug Labeling: Time to Revisit Hydroxyurea?

key information

source: The Hematologist

year: 2019

authors: Andrea Cervi, MD, MSc; Artemis Diamantouros, BScPhm, MEd, PhD; Madeleine Verhovsek, MD, FRCPC

summary/abstract:

Despite benefits in reducing pain crises, transfusions, hospitalizations, and mortality in sickle cell disease (SCD),1-5 hydroxyurea (HU) is underutilized.1,6,7 A recent Cochrane meta-analysis found no significant increase in adverse events among HU-treated patients with SCD,8 yet fears of possible adverse effects have been identified as a key barrier to HU acceptance.9-11 In light of the poor uptake of HU among the SCD population, hematologists need to fully understand patient and provider reluctance about this disease-modifying therapy.

organization: McMaster University, Canada; University of Toronto, Canada

full text source